In fact, overexpression of FGFR2 gene has been reported in breast, lung, stomach, and pancreatic cancers [3], while its down-modulation has been demonstrated in thyroid cancer [4] and in melanoma, where FGFR2 gene can even present loss-of-function mutations [5]. This evidence concerns the gene FGFR2 and thyroid cancer.